J. Carl Barrett

机构：AstraZeneca (United States) · ORCID：0000-0003-4042-9859

发表论文 572 篇 · 总被引 39724 次 · h-index 86

代表论文

• The ATR inhibitor ceralasertib potentiates cancer checkpoint immunotherapy by regulating the tumor microenvironment (2024 · Nature Communications · 被引 64)
• Next-Generation Molecular Residual Disease Assays: Do We Have the Tools to Evaluate Them Properly? (2024 · Journal of Clinical Oncology · 被引 28)
• Biomarker development for PD-(L)1 axis inhibition: a consensus view from the SITC Biomarkers Committee (2024 · Journal for ImmunoTherapy of Cancer · 被引 16)
• An artificial intelligence-based model for prediction of clonal hematopoiesis variants in cell-free DNA samples (2025 · npj Precision Oncology · 被引 10)
• Variability of Circulating Tumor DNA Levels in Plasma Samples From Patients With Advanced Non–Small-Cell Lung Cancer in the Absence of Treatment (2025 · JCO Precision Oncology · 被引 3)
• Plasma epigenomic profiling to reveal molecular correlates of response and resistance to 177Lu-PSMA-617 in metastatic castration-resistant prostate cancer (mCRPC). (2025 · Journal of Clinical Oncology · 被引 3)